Related Experiment Video
Updated: Jul 24, 2026
07:45
Acute Myocardial Infarction in Rats
Published on: February 16, 2011
DNA enzyme targeting TNF-alpha mRNA improves hemodynamic performance in rats with postinfarction heart failure
P O Iversen1, G Nicolaysen, M Sioud
1Institute for Nutrition Research, University of Oslo, 0316 Oslo, Norway. poiversen@hotmail.com
American Journal of Physiology. Heart and Circulatory Physiology
|October 23, 2001
Summary
This study shows that a DNA enzyme effectively reduced tumor necrosis factor-alpha (TNF-alpha) in heart failure models. This targeted therapy offers potential for treating heart failure by inhibiting TNF-alpha expression.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiology
Background:
- Tumor necrosis factor-alpha (TNF-alpha) plays a significant role in the pathogenesis of heart failure.
- Targeting TNF-alpha expression presents a potential therapeutic strategy for heart failure.
Purpose of the Study:
- To investigate the therapeutic potential of a nuclease-resistant DNA enzyme designed to cleave TNF-alpha mRNA.
- To evaluate the efficacy of this DNA enzyme in a rat model of postinfarction congestive heart failure.
Main Methods:
- A phosphorothioate-modified DNA enzyme was designed and tested for in vitro TNF-alpha mRNA cleavage and expression inhibition.
- Congestive heart failure was induced in rats via left coronary artery ligation.
- Rats were treated with the DNA enzyme for 4 weeks, and various physiological and molecular parameters were assessed.
Main Results:
- The DNA enzyme treatment significantly reduced left ventricular end-diastolic pressure and lung weight.
- Arterial blood pressure and myocardial blood flow were increased in treated rats.
- Treatment led to a marked decrease in TNF-alpha concentration in coronary sinus blood and reduced myocardial TNF-alpha mRNA levels.
- The DNA enzyme demonstrated sustained cleavage activity in the myocardium with no apparent toxic effects.
Conclusions:
- Nuclease-resistant DNA enzymes can effectively inhibit TNF-alpha expression in vivo.
- DNA enzyme-based therapy shows promise as a novel treatment for heart failure.
- Targeting TNF-alpha mRNA with DNA enzymes is a viable therapeutic approach for cardiovascular diseases.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...